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Background: Since there is high local failure and poor survival for unresectable esophageal squamous cell
carcinoma (ESCC), the necessity of elective node irradiation is controversial. The purpose of this study was to
investigate the failure patterns and survival in patients with locally advanced ESCC receiving involved-field
irradiation (IFI).
Methods: A retrospective study was preformed on the clinical records of patients with locally advanced ESCC, who
have received IFI with concurrent chemotherapy between January 2003 and January 2009. Comparing the target
volume and first sites of failure, patterns of failure were defined as in-field, out-of-field regional lymph node and
distant failure. The survivals were analyzed by different patterns of failure.
Results: Eighty patients were included in our study. With a median follow-up of 52.6 months, failures were
observed in 76 patients. In-field recurrence, distant metastasis, and out-of-field regional failure were seen in 53.75%,
41.25%, 30% patients, respectively. There were significant differences in OS for patients with and without in-field
(median OS 14.2 vs.17.4 m, P = 0.01)or distant failure(13.2 vs.15.9 m, P ≤ 0.0001), but not for out-of-field regional
lymph node failure(both 14.5 m, P = 0.665).
Conclusions: The solitary regional nodal failure of out-of-field was acceptable in advanced ESCC patients treated
with IFI. In-field and distant failures remained the predominant patterns and negatively impacted survival more
significantly. Further investigation is needed to establish the optimal radiotherapy field for these patients at
advanced stage.
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Esophageal cancer (EC) is the fifth most common cancer
and the forth leading cause of cancer deaths in China.
Different from the western countries, squamous-cell car-
cinoma accounts for 95% of all Chinese EC patients [1].
EC is notorious for its lymph node (LN) metastases,
which LN involvement is an early process and also skip
metastases are common. Nodal spread of esophageal tu-
mors may be extensive at initial clinical presentation.
More than 50% EC cases are diagnosed at locally* Correspondence: kongli7@sina.com; sdyujinming@126.com
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unless otherwise stated.advanced stage with obvious enlargement node, long le-
sion and/or serious esophageal invasion. For these pa-
tients, the results of a phase III randomized trial
(Radiation Therapy Oncology Group [RTOG] 85–01)
comparing chemoradiotherapy (CRT) with radiation
alone have made definitive CRT to one standard treat-
ment option [2]. But in practice, the radiation field of
EC has reached no global consensus till now. In RTOG
85–01, the range of clinical target volume (CTV) was
from the supraclavicular region to the gastroesophageal
junction. But in RTOG 94–05, 5-cm proximal and distal
margins and a 2-cm lateral margin from the borders of
the gross tumor volume (GTV) were recommended [3].
The supraclavicular nodes were included only when theLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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recent studies showed that the involved-field irradiation
(IFI, nodal target volume included only the malignant
nodes) may be feasible for some sub-group patients with
esophageal squamous-cell carcinoma (ESCC). Kawaguchi
found that IFI did not result in significant incidence of re-
gional LN failure in clinical stage I thoracic EC patients
[4]. For patients of EC receiving definitive radiotherapy,
some researchers employed three-dimensional conformal
radiotherapy (3D-CRT) without intentional elective node
irradiation (ENI) and the rate of isolate out-of-field nodal
failure was only 2-8% [4-6]. Moreover, some published re-
ports indicated that serious toxicities would occur in at
least 50% of patients with EC receiving concurrent che-
moradiation therapy (CCRT) if ENI was adopted [3,7].
Thus, IFI may result in reduced incidence of treatment
toxicities which enable more patients to tolerate the
CCRT.
To date, there have been few reports on the exclusive
use of IFI for locally advanced ESCC patients. The
present study sought to retrospectively document the
failure patterns and survival, and evaluate the feasibility
of IFI for this specific population.
Materials and methods
Patients
From 2003, the therapeutic regimen of IFI with concur-
rent chemotherapy was performed for EC patients in
our department. This retrospective study was preformed
on the clinical records of patients with locally advanced
ESCC, who have received IFI with concurrent chemo-
therapy of cisplatin (CDDP) and 5-fluorouraci (5-FU)
between January 2003 and January 2009. Patients were
excluded if they had any other malignant tumor history.
The disease had been confirmed by biopsy or brushing
and had not yet been treated before. Every patient had
been assessed and staged by examinations including eso-
phagogram, endoscopy, and computed tomography
(CT), and some by positron emission tomography
(PET)/-CT fusion scans. All of the reviewed cases had
one of the following characteristics: cervical lesion,
upper thoracic lesion with length more than 6 cm, T4
disease, or obvious (bulky or multiple) involvement of
regional lymph nodes. The institutional review board of
Shandong Cancer Hospital approved our study.
Chemoradiotherapy
All patients had been treated with definitive chemother-
apy with concurrent radiotherapy.
All radiation treatments were to be delivered as 3D-
CRT or Intensity Modulated Radiation Therapy (IMRT)
with standard fractionation (2.0 Gy fraction−1, 5 days per
week); treatment plans were generated with three-
dimensional planning system (ADAC-Pinnacle 3, version5.0). The GTV was contoured on the planning CT scans
by the attending radiation oncologists using all available
resources, including data from esophagogram, endoscopic
ultrasonography (EUS) images, diagnostic CT images and
PET/CT fusion scans. The GTV was defined as any visible
esophageal lesion (GTVe) and clinical involved node
(GTVn). The primary criterion for node metastases was
the size. The lymph nodes over 1.0 cm in the short axis or
1.5 cm in the long axis on CT scans or with a high SUV-
max of FDG avid on PET images were considered to be
metastatic. Other criteria, including the nodal enhance-
ment pattern and the presence of extra-nodal tumor ex-
tension, also had been used to help assess the
metastatic status. The CTVe was defined as the GTVe
plus a 3.0-4.0 cm margin superior and inferior to the
primary tumor and a 0.8-1.0 cm radial margin. CTVn
was defined as the GTVn plus a 0.5-1.0 cm radial margin.
The PTV was defined as the CTV plus a 0.5-1.0 cm mar-
gin. All organs at risk were outlined. Although, according
to the RTOG 85–01, chemotherapy could help to some
degree, it did not change the fact that this dose (50.4 Gy
in 28 fractions) was inadequate to achieve high probability
for local control. So in our study, all patients were treated
with a total dose of 50- 64Gy, given in 25–32 fractions,
with the median dose of 60Gy.
Chemotherapy began on day 1, concurrent with the
beginning of radiation. The chemotherapeutic regimens
consisted of two cycles of CDDP (75 mg/m2/day on
Day 1) and 5-FU (700 mg/m2/day as a continuous infu-
sion from Day 1 to Day 4) every21 days in all patients.
Additional 1–2 (median 2) cycles of chemotherapy with
the same regimens were administered for 57 patients.
Result assessment and follow-up
The tumor response and recurrence were evaluated and
classified according to the Response Evaluation Criteria
in Solid Tumors (RECIST) system [8] and the final re-
sults were recorded by the follow-up data. In brief, the
responses were classified as follows: complete response
(CR), partial response (PR), progressive disease (PD),
stable disease (SD). The overall response (RR) rate was
defined as the CR rate plus the PR rate. We assessed fail-
ure models on post treatment esophagogram, endoscopy,
CT, or PET/CT scans and compared those data with the
original CT- based radiation treatment plans. However,
when an esophageal recurrence was suspected, it was con-
firmed by histologic or cytologic testing. LN recurrences
were diagnosed on the basis of the following findings: (1)
nodes that re-appeared after complete disappearance;
(2) nodes that enlarged after remaining stable; and (3) new
nodes that appeared in the mediastinal or abdominal re-
gions where no enlarged nodes had existed before irradi-
ation. Suspected supraclavicular node recurrences were
confirmed by fine needle aspiration biopsy. Patterns of
Table 1 Patient characteristics
Patient characteristics N (%)
Sex
Male 52(65.00)
Female 28(35.00)
Age, y, median (range) 63(42–74)
Tumor category
T1-3 63(78.75)
T4 17(21.25)
Lymph node category
N0 21(26.25)
N+ 59(73.75)
Location
Cervical 2(2.50)
Upper thoracic 19(23.75)
Mid-thoracic 49(61.25)
Lower thoracic 10(12.50)
Tumor length, cm, 5.00(2–13)
Radiation dose
<60 Gy 11(13.75)
≥60 Gy 69(86.25)
Median (range), Gy 60(50-64)
Adjuvant chemotherapy
Yes 57(71.25)
No 23(28.75)
Median (range) 2(0–4)
Salvage treatment 65(81.25)
Chemotheray 32(40.00)
Palliative radiation 35(43.75)
Surgery 8(10.00)
Zhang et al. Radiation Oncology 2014, 9:64 Page 3 of 7
http://www.ro-journal.com/content/9/1/64failure were defined according to the first sites of failure
and included in-field, out-of-field regional LN and distant
failure, respectively. In-field recurrence included primary
lesion and involved regional LN failure. Out-of-field re-
gional LN failure was defined as the failure of initially un-
involved LN within the regional LN. Regional lymph
nodes were defined as periesophageal LN extending from
the cervical nodes to the celiac nodes [9]. The LN metas-
tases outside the regional level were considered as distant
failures. Overall survival (OS) and progression-free sur-
vival (PFS) were calculated from the first day of
irradiation.
Statistical analysis
Continuous variables were summarized by descriptive
statistics such as means, standard deviations, medians,
and ranges. Categorical variables were tabulated by fre-
quency and percentage. The Kaplan-Meier method and
log rank test were applied to estimate survival probabil-
ities and compare survival, respectively. Cox propor-
tional hazards models were fit to evaluate potential
associations between OS and clinical factors. The back-
ward selection procedure was used for model selections.
SPSS version 17.0 (SPSS Inc., Chicago, IL, USA) statis-
tical software was used for statistical data analysis.
Results
Patients characteristic
Complete data were available for 80 patients treated
from January 2003 to January 2009. Among of them, 11
patients underwent staging of PET. Clinical and treat-
ment characteristics were listed in Table 1.
Patterns of failure
At the time of last follow-up contact in December 2011,
failures were observed in 95% patients, with 53.75% of
in-field, 30% of out-of-field regional LN and 41.25% of
distant metastases, respectively. Among of them, twenty-
one patients were observed to fail in more than one site.
The sites of first failure were overlapped in some pa-
tients, which were shown in Figure 1. According to our
data, 60.6% patients in distant failure group were com-
panied with regional or in-field failure, while 58.3% cases
in regional recurrence group were companied with other
failures. But the in-field as only site of failure was seen
in 74.4% cases among the in-field pattern group. The
rate of in-field failure alone, distant failure alone, out-of-
field regional LN failure alone were 40%, 16.25% and
12.5%,respectively. The most common sites of out-of-
field regional LN localized in upper mediastinal (12
cases), celiac (9 cases) and supraclavicular levels (7
cases). The most common sites of distant metastases
were distant LN in 17 cases, bone 6, lung 5 and liver 5,respectively. The details of failure patterns were listed in
Table 2.
Response and survival
The RR rate was 85%, with CR in 23.75% of patients,
and PR in 61.25% of patients. At a median follow-up
period of 52.6 months (95% confidence interval [CI],
46.1-56.7 months), the median PFS time was 11.3 months
(95% CI, 8.8-13.2 months) with 1-year, 2-year, 3-year
PFS rates of 41.3%, 18.9%, 11.3% in these advanced stage
patients, respectively. And the median OS time was
14.4 months (95% CI, 13.4-15.9 months). The 1-year, 2-
year, 3-year OS rates were 86.3%, 30.0%, 18.8%, respect-
ively (Figure 2). Univariate analysis showed that OS was
associated with baseline T status (P = 0.027) and N status
(P = 0.016). According to different failure patterns, the
median survival times were 14.2 months for in-field,
14.5 months for out-of-field and 13.2 months for distant
Figure 2 The overall survival data for all patients in this study.
The 1-year, 2-year, 3-year OS rates were 86.3%, 30.0%, 18.8%,
respectively.
Figure 1 The rate of different failure patterns. Patterns of failures
are shown based on the original radiationtreatment volumes,
53.75% within the in-field volume, 30.00% within the out-of-field
regional LN, and 43.90% in the distant.
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found (P = 0.189) among these groups (Figure 3A). The
OS time of in-field, regional and distant failure alone
were 24.5 m, 35.3 m and 18.2 m (P = 0.006, Figure 3B),
respectively.
To observe the contribution of different failure patterns
to survival, we compared the survival of patients with spe-
cific pattern to all the other patients. The median OS time
for patients with in-field failure was 14.2 months (95% CI,
13.2-14.9) versus 17.4 months for those with non in-field
failure (95% CI, 14.8-19.4; P = 0.01, Figure 4A). Having a
distant failure also influenced OS time in our study. Pa-
tients without distant failure achieved a better OS than
those with distant failure (15.9, 95% CI, 12.4-16.2 vs.13.2,
11.9-15.2 months; P < 0.0001, Figure 4C). But no signifi-
cant difference was found in the median OS time for pa-
tients with or without out-of-field regional LN failure
pattern (95% CI, 14.5, 13.2-16.2 vs. 14.5, 12.4-15.7 months;
P = 0.665, Figure 4B). For the 10 cases of solitary regionalTable 2 The failure patterns
Failure patterns Patients (n)
In-field with or without others 43
In-field alone 32
Out-of-field with or without others 24
Out-of-field alone 10
Supraclavicular 3
Mediastinal 3
Celiac 4
Distant with or without others 33
Distant alone 13nodal recurrence, the median PFS and OS time were 13.2
(range 4–38) and 35.6 (range 11–45) months, respectively.
Salvage therapy
Sixty-five patients have undergone salvage treatment
after treatment failure,which including chemotherapy,
palliative radiotherapy and surgery. All of the 10 cases
with solitary regional LN failure received salvage treat-
ment. Among of them, 2 cases with supraclavicular re-
currence received lymphadenectomy and chemotherapy,
4 cases (1of supraclavicular, 3 of upper mediastinal) with
radiotherapy only, 4 of celiac failure with chemotherapy
and radiation. After the salvage treatment, 4 of the 10
cases experienced more than 24 months survival period.
Discussion
In this study, we investigated treatment results and pat-
terns of first site failure after IFI for locally advanced
ESCC. We found that in-field failure and distant metas-
tasis remained the predominant failure patterns in these
cases. Among the 76 patients with failure, the rate of
out-of-field regional LN failure alone was 12.5%. Zhao
et al. have evaluated the results of IFI for EC patients
with 3D-CRT. The rate of in-field recurrence was 44%,
but only 8% cases were isolated out-of-field nodal recur-
rences [6]. Uno et al. reported that a radiotherapy PTV
including only clinically-involved lesion for patients with
EC aged 75 and older, resulted in no isolated LN recur-
rence [10]. The concern was that the persistence of dis-
ease was the greatest cause of treatment failure (despite
therapy), and 26% of patients receiving combined ther-
apy experienced local failure. Published data has re-
ported that regional LN failure rates ranged from 5% to
15% for ENI in EC patients receiving radiotherapy [11].
Figure 3 The overall survival data for patients with different failure patterns (A) and solitary failure patterns (B). Kaplan-Meier estimates
of OS are shown according to different failure patterns (A) and solitary failure patterns (B). No significant difference in OS was found for patients
with different failure patterns (P = 0.189). But there was a significant difference in OS for patients with solitary failure patterns (P = 0.006).
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not the main pattern of recurrence in these advanced
stage ESCC patients.
In present study, we also found a longer median sur-
vival time in patients with regional failure, but there was
no statistic difference in OS time between different fail-
ure patterns. It was mainly caused by the overlap of fail-
ure sites in this population. According to our data, more
than half (58.3%) cases were companied with other sites
of failure in regional recurrence group. When we ana-
lyzed the survival with solitary failure pattern, a longest
median survival time was found in the group of regional
failure alone. Our further analysis showed that the pa-
tients with in-field or distant failure had worse survival.
But the OS for patients with and without out-field
failure showed no statistical significant difference
(P = 0.665). These data may indicate that, compared
with regional failure, the in-field and distant failure
negatively impacted survival more significantly. TheFigure 4 The overall survival data for patients with and without spec
to specific failure pattern. Significant difference in OS was found for patients w
but not in out-of-field regional failure (P = 0.665, C).relatively high incidence of in-field recurrence and dis-
tant metastasis may mask regional nodal failures be-
cause many of the patients have died before their
regional nodal failure became clinically apparent or
threat to life. So the relatively high regional control ac-
quired with ENI may not translate into the benefit of
OS, especially for advanced stage cases.
And on the other hand, if only the solitary regional
nodal failure occurred, a salvage treatment may provide
better survival. In our study, 40% (4/10) of the cases
with solitary regional failure experienced more than
24 months survival period after the salvage treatment.
Another two studies also supported the efficacy of the
salvage treatment for solitary regional node recurrence.
Yano et al. reported the result of treatment for 35 pa-
tients with the cervical LN recurrence, and concluded
that substantial survival could be attained by salvage
local-regional treatment if it was a solitary node recur-
rence [12]. Watanabe et al. performed salvage cervicalific failure pattern. Kaplan-Meier estimates of OS are shown according
ith and without in-field (P = 0.010, A), and distant failure (P < 0.0001, B),
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for all five patients with recurrence limited within the
cervical nodes, and observed no disease relapse in a me-
dian follow-up period of 54 months. The median sur-
vival period after the salvage treatment was 60 months
[13]. So the salvage treatment after regional LN failure
alone may mitigate its adverse effect on survival.
Although all the patients included in our study were in
locally advanced stage, we could still see a few patients
with long-term survival, which indicated a good response
to CCRT. Previous studies have demonstrated that only
patients with histological complete response can acquire
survival benefits [14,15]. Unfortunately, most EC patients
were resistant to chemoradiation, with only 20%–40%
pathologic CR rate after definitive CCRT in advanced
stage patients [16]. As high as 11–26% of those patients
did not exhibit any morphological response, leading to a
dismal prognosis with a median survival of only 9 months
[17]. In our opinion, for those patients of complete re-
sponder, ENI may be appropriate to eliminate microme-
tastases in regional LN, which might get longer PFS. And
for those non-responders or non complete responders,the
ENI seems unnecessary,if the primary lesions could not be
well controlled. So additional evaluations may be war-
ranted to assess the sensitivity of patients to CCRT and
then individualize treatments, thereby sparing patients un-
necessary toxicity from ineffective therapy.
However, even though the in-field failure was the most
common site (53.75%)of initial failure, patients in our
study also experienced high rate (41.25%)of systemic fail-
ure. Thus, efforts to increase local control may not ne-
cessarily translate into improved survival unless systemic
therapies also improved. The intensification of chemo-
therapy through the addition of induction chemotherapy
had been in trial to strengthen the systemic therapy, but
no consensus response was obtained until now [18,19].
To improve both local and distant control in patients
with EC, new regimens must be developed. Perhaps only
when the high local failure rate is addressed, the value of
this approach can get fully realized.
In the present study, the failure rate of more than 90%
in the whole patient group and the survival data (18.8%
for 3y) appeared worse than preceding reports. Some
factors may have contributed, in part, to the high failure
rate and worse overall survival in our study. First, all of
the patients included in our study were in locally ad-
vanced stage with wide local tumor extension and/or
clinically obviously node metastases, which was the most
important cause for bad prognosis. Second, EUS, PET
scans and other functional images were not available for
all of the cases in the trial, which might lead to diagnos-
tic underestimation, have impacted the target volume to
IFI. The microscopic disease in normal sized nodes and
LN enlargement caused by benign conditions, limit thediagnostic accuracy of CT for nodal enlargement caused
by EC. According to a meta-analysis, the sensitivity and
specificity of CT for regional lymph node metastases
were 0.50 and 0.83 in thoracic tumor, respectively [20].
In the future study, if the IFI was used, the more accur-
ate diagnostic technique should be performed to avoid
the missing of involved node. Third, ENI should be really
effective for providing regional control of LN micrometas-
tases and leading to a longer PFS, especially for respond-
ing cases who had a relatively long survival.
In summary, our study found that in-field and distant
failure remained the major failure patterns in patients with
locally advanced ESCC treated with IFI and impacted the
survival time more significantly, while the solitary nodal
failure of out-of-field was acceptable and the salvage treat-
ment for solitary regional failure may improve outcome.
The omission of elective nodal irradiation did not sacrifice
OS, to some extend, which suggested the feasibility of IFI
for the locally advanced cases. However, this was a retro-
spective study with a relatively small sample size, which
may limit the generalizability of our findings. Further ob-
servations with large-scale, multi-center, prospective,
stratification, randomized clinical trials are needed to ver-
ify the feasibility of IFI in this sub-group population.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
XZ and ML drafted the manuscript. XM, LK, YZ, GW, XZ, MH, FS, GZ
participated in data collection, and helped to analyze the data. JY
participated in the coordination of the study. All authors read and approved
the final manuscript.
Received: 23 December 2013 Accepted: 19 February 2014
Published: 26 February 2014
References
1. Chen W, He Y, Zheng R, Zhang S, Zeng H, Zou X, He J: Esophageal cancer
incidence and mortality in China, 2009. J Thorac Dis 2013, 5:19–26.
2. Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA Jr, Al-Sarraf
M, Byhardt R, Russell AH, Beitler JJ, Spencer S, Asbell SO, Graham MV,
Leichman LL: Chemoradiotherapy of locally advanced esophageal cancer:
long-term follow-up of a prospective randomized trial (RTOG 85–01).
Radiation Therapy Oncology Group. JAMA 1999, 281:1623–1627.
3. Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R,
Okawara G, Rosenthal SA, Kelsen DP: INT 0123 (Radiation Therapy
Oncology Group 94–05) phase III trial of combined-modality therapy for
esophageal cancer: high-dose versus standard-dose radiation therapy.
J Clin Oncol 2002, 20:1167–1174.
4. Kawaguchi Y, Nishiyama K, Miyagi K, Suzuki O, Ito Y, Nakamura S: Patterns
of failure associated with involved field radiotherapy in patients with
clinical stage I thoracic esophageal cancer. Jpn J Clin Oncol 2011,
41:1007–1012.
5. Welsh J, Settle SH, Amini A, Xiao L, Suzuki A, Hayashi Y, Hofstetter W,
Komaki R, Liao Z, Ajani JA: Failure patterns in patients with esophageal
cancer treated with definitive chemoradiation. Cancer 2012,
118:2632–2640.
6. Zhao KL, Ma JB, Liu G, Wu KL, Shi XH, Jiang GL: Three-dimensional
conformal radiation therapy for esophageal squamous cell carcinoma:
is elective nodal irradiation necessary? Int J Radiat Oncol Biol Phys 2010,
76:446–451.
7. Ishikura S, Nihei K, Ohtsu A, Boku N, Hironaka S, Mera K, Muto M, Ogino T,
Yoshida S: Long-term toxicity after definitive chemoradiotherapy for
Zhang et al. Radiation Oncology 2014, 9:64 Page 7 of 7
http://www.ro-journal.com/content/9/1/64squamous cell carcinoma of the thoracic esophagus. J Clin Oncol 2003,
21:2697–2702.
8. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L,
Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG:
New guidelines to evaluate the response to treatment in solid tumors.
European Organization for Research and Treatment of Cancer, National
Cancer Institute of the United States, National Cancer Institute of
Canada. J Natl Cancer Inst 2000, 92:205–216.
9. Rice TW, Rusch VW, Ishwaran H, Blackstone EH: Worldwide Esophageal
Cancer Collaboration. Cancer of the esophagus and esophagogastric
junction: data-driven staging for the seventh edition of the American
Joint Committee on Cancer/International Union Against Cancer Cancer
Staging Manuals. Cancer 2010, 116:3763–3773.
10. Uno T, Isobe K, Kawakami H, Ueno N, Kobayashi H, Shimada H, Mastubara H,
Okazumi S, Nabeya Y, Shiratori T, Ochiai T, Kawata T, Ito H: Efficacy and
toxicities of concurrent chemoradiation for elderly patients with
esophageal cancer. Anticancer Res 2004, 24:2483–2486.
11. Onozawa M, Nihei K, Ishikura S, Minashi K, Yano T, Muto M, Ohtsu A, Ogino
T: Elective nodal irradiation (ENI) in definitive chemoradiotherapy (CRT)
for squamous cell carcinoma of the thoracic esophagus. Radiother Oncol
2009, 92:266–269.
12. Yano M, Takachi K, Doki Y, Miyashiro I, Kishi K, Noura S, Eguchi H, Yamada T,
Ohue M, Ohigashi H, Sasaki Y, Ishikawa O, Matsunaga T, Imaoka S:
Prognosis of patients who develop cervical lymph node recurrence
following curative resection for thoracic esophageal cancer.
Dis Esophagus 2006, 19:73–77.
13. Watanabe M, Nishida K, Kimura Y, Miyazaki M, Baba H: Salvage
lymphadenectomy for cervical lymph node recurrence after
esophagectomy for squamous cell carcinoma of the thoracic esophagus.
Dis Esophagus 2012, 25:62–66.
14. Kersting S, Konopke R, Dittert D, Distler M, Rückert F, Gastmeier J, Baretton
GB, Saeger HD: Who profits from neoadjuvant radiochemotherapy for
locally advanced esophageal carcinoma? J Gastroenterol Hepatol 2009,
24:886–895.
15. Stahl M, Wilke H, Stuschke M, Walz MK, Fink U, Molls M, Siewert JR,
Schroeder M, Makoski HB, Schmidt U, Seeber S, Vanhoefer U: Clinical
response to induction chemotherapy predicts local control and
long-term survival in multimodal treatment of patients with locally
advanced esophageal cancer. J Cancer Res Clin Oncol 2005, 131:67–72.
16. Zhong Z, Gu X, Zhang Z, Wang D, Qing Y, Li M, Dai N: Recombinant
human endostatin combined with definitive chemoradiotherapy as
primary treatment for patients with unresectable but without systemic
metastatic squamous cell carcinoma of the oesophagus. Br J Radiol 2012,
85(1019):e1104–e1109.
17. Piessen G, Briez N, Triboulet JP, Mariette C: Patients with locally advanced
esophageal carcinoma nonresponder to radiochemotherapy: who will
benefit from surgery? Ann Surg Oncol 2007, 14:2036–2044.
18. Murakami M, Kuroda Y, Matsusue S, Okamoto Y, Nakajima T, Nishimura S,
Kusumi F, Hajiro K, Takeda H: Treatment results of esophageal carcinoma
of clinical T3, T4M0: historical comparison between neoadjuvant
chemoradiotherapy followed by surgery or definitive radiotherapy and
conventional surgery. Oncol Rep 2000, 7:571–578.
19. Watanabe M, Nagai Y, Kinoshita K, Saito S, Kurashige J, Karashima R,
Hirashima K, Sato N, Imamura Y, Hiyoshi Y, Baba Y, Iwagami S, Miyamoto Y,
Iwatsuki M, Hayashi N, Baba H: Induction chemotherapy with docetaxel/
cisplatin/5-fluorouracil for patients with node-positive esophageal
cancer. Digestion 2011, 83:146–152.
20. de Langen AJ, Raijmakers P, Riphagen I, Paul MA, Hoekstra OS: The size of
mediastinal lymph nodes and its relation with metastatic involvement:
a meta-analysis. Eur J Cardiothorac Surg 2006, 29:26–29.
doi:10.1186/1748-717X-9-64
Cite this article as: Zhang et al.: Involved-field irradiation in definitive
chemoradiotherapy for locally advanced esophageal squamous cell
carcinoma. Radiation Oncology 2014 9:64.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
